RCS - Oxford Biomedica PLC - OXB Launches Advisory Board

Oxford BioMedicaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC1169La&default-theme=true

RNS Number : 1169L  Oxford Biomedica PLC  03 June 2025

 

 

 

OXB Highlights the Launch of its Innovation and Technology Excellence Board

Oxford, UK - 03 June 2025: OXB (LSE: OXB) ("the Company"), a global quality
and innovation-led cell and gene therapy CDMO, today highlights the launch of
its Innovation and Technology Excellence Board (ITEB). The ITEB brings
together leading experts in cell and gene therapy, scientific innovation, and
advanced manufacturing. It will advise OXB on technology priorities,
innovation opportunities and emerging trends that support the Company's growth
as a pure-play CDMO.

 

The newly formed advisory board, which held its inaugural meeting last month,
will identify opportunities to enhance scientific capabilities to ensure that
OXB remains at the forefront of developing innovative technologies. This
strategic insight will allow OXB to further enhance its value proposition to
clients, while strengthening its market-leading position in the cell and gene
therapy space.

 

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "The Innovation
and Technology Excellence Board marks a key step in OXB's evolution as a
pure-play CDMO focused on delivering best-in-class innovation for our clients.
By bringing together some of the most respected voices in cell and gene
therapy and biomanufacturing, we are creating a structure that will help us
stay ahead of scientific and technological change, improve the way we work,
and ultimately help our clients bring transformative therapies to patients."

 

Professor Dame Kay Davies DPhil FRS, Chair of OXB's Innovation and Technology
Excellence Board, added: "Cell and gene therapy continues to evolve quickly,
and staying on top of that progress requires both scientific depth and
external perspective. ITEB brings together a range of expertise to help OXB
focus its innovation where it matters most: improving the way treatments are
developed, manufactured and delivered. Our goal is to ensure that innovation
leads to practical advances for OXB's clients and better outcomes for
patients."

 

Founding members of OXB's Innovation and Technology Excellence Board are:

 

Prof. Dame Kay Davies DPhil FRS (ITEB Committee Chair and Senior Independent
Non-Executive Director of OXB) is among the most respected figures in human
genetics, known for her research into the molecular basis of neuromuscular and
neurological disease. She is Emeritus Dr. Lee's Professor of Anatomy and
Co-Director of the MDUK Oxford Neuromuscular Centre at the University of
Oxford. Prof. Davies  sits on the boards of UCB S.A. and Thomas White Oxford
Ltd, she co-founded Summit Therapeutics plc and served as Deputy Chair of the
Wellcome Trust (2013-2017).

 

Prof. Uwe Buecheler, PhD, is a leading molecular biologist and
biopharmaceutical executive with over 30 years of industry experience. He
previously served as Head of the Biopharma Business Unit at Boehringer
Ingelheim, overseeing global operations and the launch of more than 30
biologics. He is currently a Member of Supervisory Boards of Biotech companies
and Non-Executive Director of BioPhorum, a company driving progress and
fostering collaboration within the biopharmaceutical industry. He also chairs
the Biopharma Cluster South Germany and advises biotech companies on CMC
development and biomanufacturing strategy.

 

Prof. Bruce Levine, PhD, is the Barbara and Edward Netter Professor in Cancer
Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production
Facility at the University of Pennsylvania. He is co-inventor of Kymriah, the
first FDA-approved CAR T cell therapy for leukaemia and lymphoma and has led
pioneering first-in-human trials in cell and gene therapy. He is a co-founder
of Tmunity and Capstan Therapeutics, holds over 30 US patents and has
published more than 200 scientific papers. He is a Past President of the
International Society for Cell and Gene Therapy and serves on the board of the
Alliance for Cancer Gene Therapy.

 

Prof. Axel Schambach, MD, PhD, is Director of the Institute of Experimental
Hematology and Professor for Gene Modification of Somatic Cells at Hannover
Medical School. His research focuses on the molecular pathophysiology of
inborn and acquired diseases, with an emphasis on developing innovative gene
therapy strategies, including novel vector systems and genome editing tools.
He has received prestigious European grants for his pioneering work on gene
therapies for hearing loss and is recognised for advancing precision genome
editing and translational gene therapy. Prof. Schambach has contributed to a
number of cell and gene therapy clinical trials.

 

Prof. Luk Vandenberghe, PhD, is the Grousbeck Associate Professor in Gene
Therapy at Harvard Medical School and Director of the Grousbeck Gene Therapy
Center at Mass Eye and Ear and Mass General Brigham. A pioneer in AAV gene
therapy, he co-invented AAV9 and has advanced novel vector technologies for
treating neurosensory and other disorders. He has co-founded GenSight
Biologics, Akouos, Affinia Therapeutics and the non-profit Odylia
Therapeutics. Prof. Vandenberghe holds over 30 patents with more than 100
peer-reviewed publications in gene therapy research.

 

Dr. Heather Preston (Observer and Independent Non-Executive Director of OXB)
has over 30 years of experience in healthcare as a scientist, physician and
management consultant and has been an investor in life sciences and
biotechnology for more than 20 years. Over the course of her career, Dr.
Preston has also served as a director on the boards of Oxford Science
Enterprises plc, Karuna Pharmaceuticals and Akouos Inc. Dr. Preston  also
sits on the boards of Oxford Nanopore Technologies plc and Aligos
Therapeutics, a Nasdaq-listed company. In addition, she is a Senior Advisor to
TPG Biotech. Dr. Preston holds a degree in Medicine from the University of
Oxford.

 

The following members of OXB's senior leadership team also sit on the
Innovation and Technology Excellence Board:

 

Dr. Frank Mathias (Chief Executive Officer of OXB) brings over 30 years of
leadership experience in the biopharmaceutical and CDMO sectors. Prior to
joining OXB, Dr. Mathias was previously the CEO of Rentschler Biopharma SE,
which he successfully developed into a leading global, full-service CDMO.
Prior to Rentschler, Dr. Mathias was CEO of Medigene AG, a publicly listed
immuno-oncology company focusing on the development of T-cell-based cancer
therapies. He is currently the Chairman of the Board of Directors of
ArcticZymes Technologies ASA, a supplier of best-in-class enzyme technologies.
Dr. Mathias has also served in senior roles at leading global pharmaceutical
companies including Amgen Deutschland GmbH, Servier Deutschland GmbH and
Hoechst AG and, in 2019, was awarded the title of "EY Entrepreneur of the
Year" in Germany. Dr. Mathias is a pharmacist by training and completed his
Doctorate in Pharmacy at Paris VI University.

 

Thierry Cournez (Chief Operating Officer of OXB) has extensive experience in
Sales, Marketing and GMP/GLP operations, with broad industry knowledge in the
life science, biopharma and CDMO ecosystems. Prior to joining OXB, he served
as Vice President of Global Testing Operations Bioreliance(®) at Merck Life
Science, where he successfully managed large capacity expansion projects and
held international responsibility for contract testing operations across the
US, UK, Singapore and China. Prior to this, in his role as Vice President of
End-to-End Bioprocessing Solutions, Mr. Cournez built and developed Merck Life
Science's End-to-End Promise Venture business unit, which involved the
delivery and implementation of CDMO solutions for biopharma clients. Mr.
Cournez holds an Engineer's Degree in Biochemistry and Molecular Biology from
INSA, Lyon, alongside a Master's of Science in Molecular Biology from Paris VI
University.

 

Dr. Kyriacos Mitrophanous (Chief Innovation Officer of OXB) has over 30 years
of lentiviral vector experience covering a range of technical disciplines,
including the development of cell and gene therapies, delivery platform
technologies, bioprocessing and analytics. Dr. Mitrophanous is a recognised
world-class expert in the field, a named inventor on numerous lentiviral
vector patents and an author of a number of key papers. In his current role,
he is responsible for all aspects regarding client focussed innovation. He
holds a PhD in Molecular Biology from University College London and has
conducted post-doctoral research at the University of Oxford.

 

Dr. Sébastien Ribault (Chief Business Officer of OXB) has over 25 years of
experience across the biotechnology industry and CDMO space. Dr. Ribault  was
previously at Merck Life Science where he was Vice President & Head of
Biologics and Viral Vector CDMO, leading Merck's CDMO expansion project,
establishing the Services business case and helping to establish the Life
Science Services business unit. Prior to his 17 years with Merck Life Science,
Dr. Ribault was a Gene Therapy Development Scientist at Transgene and Head of
the R&D Laboratory at Hemosystem. He has a PhD in Molecular and Cellular
Biology from the University of Strasbourg.

 

 

-Ends-

 

Enquiries:

 

OXB:

Dr. Kyriacos Mitrophanous, Chief Innovation Officer - T: +44 (0) 1865 783 000
/ E: partnering@oxb.com (mailto:partnering@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica)  and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGGVZZDGKZZ